The impact of bleeding complications in patients receiving target-specific oral anticoagulants: A systematic review and meta-analysis

© 2014 by The American Society of Hematology. Vitamin Kantagonists (VKAs) have been the standard of care for treatment of thromboembolic diseases. Target-specific oral anticoagulants (TSOACs) have been developed and found to be at least noninferior to VKAs with regard to efficacy, but the risk of bl...

Full description

Saved in:
Bibliographic Details
Main Authors: Chatree Chai-Adisaksopha, Mark Crowther, Tetsuya Isayama, Wendy Lim
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84907662267&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/53179
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-53179
record_format dspace
spelling th-cmuir.6653943832-531792018-09-04T09:56:24Z The impact of bleeding complications in patients receiving target-specific oral anticoagulants: A systematic review and meta-analysis Chatree Chai-Adisaksopha Mark Crowther Tetsuya Isayama Wendy Lim Biochemistry, Genetics and Molecular Biology Immunology and Microbiology Medicine © 2014 by The American Society of Hematology. Vitamin Kantagonists (VKAs) have been the standard of care for treatment of thromboembolic diseases. Target-specific oral anticoagulants (TSOACs) have been developed and found to be at least noninferior to VKAs with regard to efficacy, but the risk of bleeding with TSOACs remains controversial. We performed a systematic review and meta-analysis of phase-3 randomized controlled trials (RCTs) to assess the bleeding side effects of TSOACs compared with VKAs in patients with venous thromboembolism or atrial fibrillation. We searched MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials; conference abstracts; and www.clinicaltrials.gov with no language restriction. Two reviewers independently performed study selection, data extraction, and study quality assessment. Twelve RCTs involving 102 607 patients were retrieved. TSOACs significantly reduced the risk of overall major bleeding (relative risk [RR] 0.72, P < .01), fatal bleeding (RR 0.53, P < .01), intracranial bleeding (RR 0.43, P < .01), clinically relevant nonmajor bleeding (RR 0.78, P < .01), and total bleeding (RR 0.76, P < .01). There was no significant difference in major gastrointestinal bleeding between TSOACs and VKAs (RR 0.94, P 5 .62). When compared with VKAs, TSOACs are associated with less major bleeding, fatal bleeding, intracranial bleeding, clinically relevant nonmajor bleeding, and total bleeding. Additionally, TSOACs do not increase the risk of gastrointestinal bleeding. 2018-09-04T09:44:46Z 2018-09-04T09:44:46Z 2014-10-09 Journal 15280020 00064971 2-s2.0-84907662267 10.1182/blood-2014-07-590323 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84907662267&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/53179
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Biochemistry, Genetics and Molecular Biology
Immunology and Microbiology
Medicine
spellingShingle Biochemistry, Genetics and Molecular Biology
Immunology and Microbiology
Medicine
Chatree Chai-Adisaksopha
Mark Crowther
Tetsuya Isayama
Wendy Lim
The impact of bleeding complications in patients receiving target-specific oral anticoagulants: A systematic review and meta-analysis
description © 2014 by The American Society of Hematology. Vitamin Kantagonists (VKAs) have been the standard of care for treatment of thromboembolic diseases. Target-specific oral anticoagulants (TSOACs) have been developed and found to be at least noninferior to VKAs with regard to efficacy, but the risk of bleeding with TSOACs remains controversial. We performed a systematic review and meta-analysis of phase-3 randomized controlled trials (RCTs) to assess the bleeding side effects of TSOACs compared with VKAs in patients with venous thromboembolism or atrial fibrillation. We searched MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials; conference abstracts; and www.clinicaltrials.gov with no language restriction. Two reviewers independently performed study selection, data extraction, and study quality assessment. Twelve RCTs involving 102 607 patients were retrieved. TSOACs significantly reduced the risk of overall major bleeding (relative risk [RR] 0.72, P < .01), fatal bleeding (RR 0.53, P < .01), intracranial bleeding (RR 0.43, P < .01), clinically relevant nonmajor bleeding (RR 0.78, P < .01), and total bleeding (RR 0.76, P < .01). There was no significant difference in major gastrointestinal bleeding between TSOACs and VKAs (RR 0.94, P 5 .62). When compared with VKAs, TSOACs are associated with less major bleeding, fatal bleeding, intracranial bleeding, clinically relevant nonmajor bleeding, and total bleeding. Additionally, TSOACs do not increase the risk of gastrointestinal bleeding.
format Journal
author Chatree Chai-Adisaksopha
Mark Crowther
Tetsuya Isayama
Wendy Lim
author_facet Chatree Chai-Adisaksopha
Mark Crowther
Tetsuya Isayama
Wendy Lim
author_sort Chatree Chai-Adisaksopha
title The impact of bleeding complications in patients receiving target-specific oral anticoagulants: A systematic review and meta-analysis
title_short The impact of bleeding complications in patients receiving target-specific oral anticoagulants: A systematic review and meta-analysis
title_full The impact of bleeding complications in patients receiving target-specific oral anticoagulants: A systematic review and meta-analysis
title_fullStr The impact of bleeding complications in patients receiving target-specific oral anticoagulants: A systematic review and meta-analysis
title_full_unstemmed The impact of bleeding complications in patients receiving target-specific oral anticoagulants: A systematic review and meta-analysis
title_sort impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84907662267&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/53179
_version_ 1681424087208951808